Thiazolidinedione use and risk of hospitalization for pneumonia in type 2 diabetes: population based matched case-control study
Abstract
Corresponding author: Sonal Singh
How to cite: Singh S, Yen Chang H, Richards T et al. Thiazolidinedione use and risk of hospitalization for pneumonia in type 2 diabetes: population based matched case-control study [version 1; referees: 2 approved with reservations]. F1000Research 2013, 2:145 (doi: 10.12688/f1000research.2-145.v1)Copyright: © 2013 Singh S et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
Competing interests: The authors have no competing interests. The dataset used in this study was created for a research project on the patterns of obesity care within selected BlueCross BlueShield health insurance plans. The original development of the dataset was funded by unrestricted research grants from Ethicon Endo-Surgery, Pfizer, and GlaxoSmithKline. Data and database development support were provided by the BlueCross BlueShield Association (Tennessee, Hawaii, Michigan, and North Carolina), Highmark (Pennsylvania), Independence BlueCross (Pennsylvania), and Wellmark BlueCross BlueShield (Iowa and South Dakota). The BlueCross BlueShield plans were invited to review the manuscript but they did not have any direct role in the design and conduct of the study, data management or analysis, interpretation of the data, or preparation of the manuscript.First published: 27 Jun 2013, 2:145 (doi: 10.12688/f1000research.2-145.v1)Latest published: 27 Jun 2013, 2:145 (doi: 10.12688/f1000research.2-145.v1)
Introduction
The thiazolidinediones, rosiglitazone and pioglitazone, are peroxisome proliferator-activated receptor γ (PPARγ) agonists. These drugs effectively lower glycated hemoglobin levels among patients with type 2 diabetes1. Both these agents have relatively similar efficacy, but may have different adverse effect profiles1–8. Since regulatory approval, the thiazolidinediones have been associated with an increase in the risk of fractures in women, heart failure and, in the case of rosiglitazone, myocardial infarction1–6. Certain immunological adverse effects such as increased risk of bladder cancer7, or acute cholecystitis9, are specific to pioglitazone.
Rosiglitazone is a PPARγ agonist, whereas pioglitazone has both α and γ effects. PPARγ activation may result in glucorticoid like effects in the airways10–12. These effects could induce susceptibility to pneumonia similar to the effect of glucorticoids in chronic obstructive pulmonary disease13. In human macrophages the thiazolidinediones have off-target effects on PPARδ at clinically relevant doses14–17. This augmentation of PPARδ signaling by the thiazolidinediones may potentially exhibit proinflammatory activities such as pneumonia14,15.
Patients with type 2 diabetes are known to be at a higher risk of pneumonia18,19. A large, long term clinical trial7, and a meta-analysis of long term clinical trials raised the possibility that long term use (> one year) of the thiazolidinediones may increase the risk of pneumonia6. We aimed to test the hypothesis that the use of rosiglitazone or pioglitazone was associated with an increased risk of pneumonia in patients with type 2 diabetes.
Methods
Setting
We used administrative claims data from seven US Blue Cross and Blue Shield (BCBS) plans. These were the BCBS of Tennessee, Hawaii, Michigan, North Carolina; Highmark, Inc. of Pennsylvania, Independence Blue Cross of Pennsylvania and Wellmark, Inc. of Iowa and of South Dakota.
Study design and population
We assembled an incipient cohort of all patients with type 2 diabetes who filled at least one prescription for any hypoglycemic agent between 2002 and 2008. To be eligible for inclusion, individuals had to be: a) between 18 and 64 years on their first date of diagnosis of diabetes, b) contribute at least 6 months of medical or pharmacy coverage in the calendar year of diabetes diagnosis; c) of known sex; d) without any claim for congestive heart failure. We restricted the analytical sample to cases of pneumonia without a history of diagnosis of congestive heart failure to reduce outcome misclassification because congestive heart failure is a known adverse effect of thiazolidinedione use and shares many clinical and radiographic similarities to pneumonia4. We determined eligibility for the study from computerized encounter data including enrollment files for administrative data; benefits information to determine medical and pharmacy coverage; and inpatient, outpatient, and pharmacy claims records containing Common Procedural Terminology (CPT) codes, International Classification of Disease-9 Clinical Modification (ICD-9-CM) codes, and National Drug Codes (NDC) or Diagnosis Related Group (DRG) codes and costs and charges (submitted, allowed, and paid).
Selection of cases
Briefly, we identified presumptive cases by using an algorithm of ICD-9 codes for inpatient pneumonia (Supplementary Table 1). These were defined as individuals with an inpatient code for pneumonia. For people with multiple episodes of pneumonia, we included only the first episode.
Selection of controls
We selected one control for each case from the eligible source population matched on age (10 year intervals), sex, insurance plan site, and Diabetes Complication Severity Index (0, 1, and 2)20,21, and enrollment pattern or duration of pneumonia-free follow-up (incidence density sampling). Pneumonia cases were not eligible to be resampled as controls.
Exposure definitions
Prescription data were used as an indicator of drug exposure using NDC codes. We obtained information about thiazolidinedione use from a computerized pharmacy database containing the date the prescription was filled and number of days supplied. We used these data elements to determine the dates a patient was exposed to the drug prior to the first observed diagnosis of pneumonia.
Drug exposure was defined as having filled a prescription on any day for rosiglitazone or pioglitazone prior to the first observed diagnosis of pneumonia. A first exposure after the index diagnosis of pneumonia with thiazolidinediones was counted as unexposed. We defined four categories of exposure. Any users were those with exposure to the thiazolidinediones after the diagnosis of diabetes before the index date of pneumonia. Current users were those who were exposed to the thiazolidinediones within 60 days prior to the index date of onset of pneumonia. Recent users were those with a claim for the thiazolidinediones from 61 days to 2 years prior to the index date of pneumonia. Non-users are defined as those for whom there was no thiazolidinedione prescription or a prescription more than 2 years prior to the index date of pneumonia. Current users, recent users and non-users were mutually exclusive categories of exposure. However, any users included current and recent users.
Statistical analysis
We calculated proportions for categorical variables and means or medians for continous variables according to the case status. We used conditional logistic regression to estimate the McNemars Odds Ratio for exposure to rosiglitazone or pioglitazone to account for the matching design of the study. We evaluated rosiglitazone and pioglitazone separately. However, we did not distinguish between single agent vs. combinations of the thiazolidinediones with other oral hypoglycemic agents. We conducted analyses for recent and current rosiglitazone and pioglitazone users and for any users in a series of statistical models. The most parsimonious model only took into account the matched design of the study (age, sex, enrollment pattern, and Diabetes Complication Severity Index). Subsequent statistical models adjusted for potential confounders specified a priori using a review of the literature including chronic obstructive pulmonary disease, tobacco use, receipt of influenza or pneumococcal vaccination, and an indicator of general morbidity level (the resource utilization band from the Johns Hopkins Adjusted Clinical Group case-mix system; Supplementary Table 2)23. The fully adjusted models adjusted for matching variable, confounders and recent and current exposure of both rosiglitazone and pioglitazone. We used SAS version 9.2 for analysis. Statistical significance was set at two sided P=0.05.
Results
Study population
We found 1,100,899 patients with type 2 diabetes who were potentially eligible during the study period. Within this group 5.8% of participants (n=64,157) experienced a first episode of inpatient pneumonia during the study period. After excluding participants above 64 or below the age of 18 years (n=31,347), participants with incomplete coverage (n=24,402), missing information on sex (1,761) a history of congestive heart failure (34,589) or a date of diabetesdiagnosis later than or equal to date of pneumonia (14,150), 8883 cases of pneumonia remained eligible for inclusion. We removed two pairs of cases and controls for using both rosiglitazone and pioglitazone in the same study period. We restricted the analysis to 6129 cases of pneumonia without a history of congestive heart failure. 6129 controls matched for age, sex, and enrollment pattern and diabetes complication severity index were randomly selected from a pool of 428,826 potentially eligible controls. The flow of participants through the study is shown in Figure 1.
Characteristics
The characteristics of the cases and controls are shown in Table 1. The mean age of participants in the study was 52 years. Just over 50% of participants were male. Cases with pneumonia were more likely than controls to have chronic obstructive pulmonary disease, cancer, or be tobacco users, or to have received influenza and pneumococcal vaccination. More cases than controls were exposed to the thiazolidinediones during the study period (any exposure). The exposure of cases and controls to rosiglitazone and pioglitazone in various exposure windows is shown in Table 2.
Association between thiazolidinedione use and hospitalization for pneumonia
Our results for Model 1, Model 2, Model 3 and Model 4 are shown in Table 3. After adjusting for COPD cancer, tobacco use, and receipt of influenza and pneumococcal vaccination, and exposure in other periods in the fully adjusted model, neither recent exposure to pioglitazone (adjusted Odds Ratio (aOR), 1.15, 1.27, 95% confidence intervals 1.00–1.32), rosiglitazone (aOR 1.09, 95% CI, 0.83 1.44) nor current exposure to pioglitazone within 60 days (aOR, 1.04, 95% CI, 0.60–1.79) was associated with statistically significant odds of pneumonia. Current exposure to rosiglitazone was associated with statistically significant reduction in the odds of pneumonia (aOR, 0.33, 95% CI 0.11–0.95).
Discussion
We did not find any evidence to support our initial hypothesis that either rosiglitazone or pioglitazone was associated with a statistically significant increased risk of hospitalization for pneumonia in a restricted sample of adult patients with type 2 diabetes without a history of congestive heart failure. We also noted some unexpected findings such as a statistically significant reduction in the risk of pneumonia with rosiglitazone of ≈ 70%. There is no biological evidence to support such a beneficial effect of rosiglitazone on infections such as pneumonia. Such post-hoc findings from observational studies should be noted with caution. It is also possible that some unmeasured confounders or potentially a healthy user effect could explain these results. We did not have access to clinical records to fully evaluate the healthy user effect.
Comparison with meta-analysis of randomized controlled trials
Our findings need to be interpreted in the context of other studies. The largest 4 year clinical trial of pioglitazone, the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study NCT00174993) reported a statistically significant increased risk of pneumonia reported as serious adverse events ( Relative Risk (RR) 1.53, 95% CI 1.00–2.34: P=0.047) compared to placebo7. However a similar, large, long term clinical trial of rosiglitazone, the Rosiglitazone Evaluated for Cardiovascular outcomes in ORal agent combination therapy for type 2 Diabetes (RECORD) study did not detect a significantly increased risk of pneumonia with rosiglitazone as compared to metformin or sulfonylureas (RR 1.18, 95% CI 0.75–1.84; P=0.56)8. A previous meta-analysis of thirteen long-term (>1 year) randomized trials of the thiazolidinediones, which included the two long-term studies just mentioned, reported a ≈ 40% increased risk of pneumonia or lower respiratory tract infection adverse events or serious adverse events with statistically significant RRs for pioglitazone (RR 1.63; 95% CI 1.09–2.46) but not for rosiglitazone (RR 1.26; 95% CI 0.90–1.76)6.
There are several possible reasons for the divergent findings between this observational study and the previous meta-analysis. It is possible that participants in the trials were different from this observational study. Some trials did not report on pneumonia events, and missing data are possible in both the trial and the observational study. Although chest X-rays were adjudicated in the largest trial for pioglitazone7, it is possible that the clinical trials reported more events of pneumonia associated with the thiazolidinediones because patients on the thiazolidinediones in the trials probably received more radiographic studies to evaluate congestive heart failure associated with the thiazolidinedione (i.e. detection bias)22. In this study, we restricted our analysis to patients without congestive heart failure, which could have accounted for misclassification of outcomes.
Strengths of the study
The present study minimized the impact of the potential misclassification of congestive heart failure, a known adverse effect of thiazolidinedione use25, by restricting the analysis to hospitalized patients with pneumonia and without congestive heart failure. We also used a new user design, which is important in studying the effects of drugs to remove prevalent user biases. In addition we were able to control for several available confounders.
Limitations of the study
Our study has some limitations. Misclassification of exposure is possible because information on exposure was derived from pharmacy claims, and we cannot guarantee that the drugs were ingested. Differential misclassification of exposure ascertainment among cases and controls is unlikely but cannot be definitively ruled out. We did not impute for missing data. Although we restricted our analysis to participants without congestive heart failure to minimize potential differential misclassification of heart failure, we did not have access to the clinical records to confirm the diagnosis of pneumonia so potential outcome misclassification of congestive heart failure as pneumonia is still possible. Other database studies suggest that the positive predictive value of using a claims database to detect individuals with pneumonia is around 93%24. Our findings are not generalizable to patients above the age of 65 who were excluded from the analysis. We were not able to evaluate dose-responsiveness of the association or the specific subtypes of pneumonia (viral or bacterial) and the subsequent outcomes from the pneumonia. Residual confounding is always possible in a database study as administrative databases are limited in their ability to identify occupational exposures and other risk-factors for pneumonia such as smoking. We did not adjust for inhaled corticosteroid use, which has been shown to increase the risk of pneumonia in patients with COPD to avoid over adjustment of proximal confounders13.
What is already known on this topic and what this study adds
Rosiglitazone and pioglitazone are used to lower glycated haemoglobin in patients with type 2 diabetes. Previous clinical trials and meta-analysis have raised the possibility that thiazolidinedione use may increase the risk of infections such as pneumonia. In this study of US adults with type 2 diabetes thiazolidinedione use was not associated with a statistically significant increased risk of pneumonia.
Unanswered questions and future research
Further studies with validation of pneumonia diagnosis with clinical and radiographic information are needed. Other methods, such as the use of instrumental variables, to control for confounding by indication may offer additional insight. Further studies are required to elucidate the role of PPAR agonists off-target and glucocorticoid effects in the development of serious infections such as pneumonia.
Conclusions
Despite these limitations, our findings have implications. In this administrative database study of US adults with type 2 diabetes, we did not detect a significant increased risk of pneumonia with the thiazolidinediones. The unusually large protective effect of current exposure to rosiglitazone may reflect the healthy user effect or unmeasured confounding. Clinicians should carefully balance the benefits of thiazolidinediones on glycemic control against their known risks, after eliciting patient preferences for various outcomes in a shared decision making context.
Comments
Post a Comment